SCHEMBL3217145

SCHEMBL3217145

CNc1ncccc1CNc1cccc(Oc2cc(=O)[nH]c3ccccc23)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
GAA P10253 3/20 0.45
PTK6 Q13882 2/20 0.39
GRM5 P41594 1/20 0.38
MAPT P10636 5/20 0.37
TDP1 Q9NUW8 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
IDH1 O75874 1/20 0.37
L3MBTL1 Q9Y468 4/20 0.36
ALDH1A1 P00352 3/20 0.36
ALPG P10696 1/20 0.36
HPGD P15428 1/20 0.36
KDR P35968 1/20 0.35
MAP2K7 O14733 1/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
BRD4 O60885 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429366 0.89 MEN1 (0.43) KMT2AMEN1GAAPTK6GRM5
SCHEMBL3222479 0.87 MEN1 (0.41) KMT2AMEN1GAAMAPTTDP1
SCHEMBL13429313 0.87 GAA (0.53) KMT2AMEN1GAAPTK6MAPT
SCHEMBL13428972 0.87 GAA (0.44) KMT2AMEN1GAAPTK6GRM5
SCHEMBL3214616 0.87 VCP (0.45) KMT2AMEN1GAAPTK6GRM5
SCHEMBL13429358 0.86 MEN1 (0.45) KMT2AMEN1GAAPTK6GRM5
SCHEMBL13429256 0.82 MAOA (0.44) KMT2AMEN1GAAPTK6GRM5
SCHEMBL13429262 0.79 F2 (0.46) KMT2AMEN1GAAPTK6LMNA
SCHEMBL3214639 0.79 SMN1; SMN2 (0.49) KMT2AMEN1GAAPTK6MAPT
SCHEMBL13429316 0.79 KMT2A (0.52) KMT2AMEN1GAAPTK6GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA KMT2A 2445/4885MEN1 2648/4885GAA 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.